Currently, there are six medications approved by the European Medicines Agency and the Food and Drug Administration for long-term obesity management: orlistat, an extended-release naltrexone/bupropion combination, the glucagon-like peptide 1 receptor agonists (GLP-1RAs) liraglutide and semaglutide, and the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA) tirzepatide [14]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.